Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study

Authors: Gianni, Luca, Bisagni, Giancarlo, Colleoni, Marco, Del Mastro, Lucia, Zamagni, Claudio, Mansutti, Mauro, Zambetti, Milvia, Frassoldati, Antonio, De Fato, Raffaella, Valagussa, Pinuccia, Viale, Giuseppe

Source: In The Lancet Oncology February 2018 19(2):249-256

Brentuximab Vedotin in CD30-Expressing Germ Cell Tumors After Chemotherapy Failure

Authors: Necchi, Andrea, Anichini, Andrea, Raggi, Daniele, Giannatempo, Patrizia, Magazzù, Domenico, Nicolai, Nicola, Colecchia, Maurizio, Paolini, Biagio, Coradeschi, Elisa, Tassi, Elena, Grazia, Giulia, Mortarini, Roberta, Calareso, Giuseppina, De Fato, Raffaella, Togliardi, Elena, Crippa, Flavio, Salvioni, Roberto, Valagussa, Pinuccia, Gianni, Alessandro M.

Source: Clinical genitourinary cancer. 14(4):261-264.e4

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100033802874.0x000001&indx=1&recIds=ETOCvdc_100033802874.0x000001

This result is not displayed to guests.
Login for full access.